secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUCELL CORP /DE/ (ICCC)
CIK:        0000811641
Form:       8-K
Filed at:   2024-04-09T23:59:59+00:00
Accession:  0001213900-24-031589
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmuCell reports record Q1 2024 sales of $7.3M, up 111% YoY
-----------------------------------------------------------

- Total sales for Q1 2024: $7.3M, 111% increase from $3.4M in Q1 2023.
- Trailing twelve-month sales ended Mar 31, 2024: $21.3M, up 33% from $16.0M.
- Backlog of orders $9.1M at Mar 31, 2024, down from $9.4M Dec 2023 but up from $2.5M Dec 2022.
- Company expects FDA response on Re-Tain CMC Technical Section by May 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/811641/000121390024031589/0001213900-24-031589-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/811641/000121390024031589/ea0203580-8k_immucell.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-031589

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer